#### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

# **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Line 173-174; Page 6 anti-ADCY9 (1:1000; AP50059; Abcepta; China) anti-GAPDH (1:10000; 10494-1-AP; Proteintech; China) Line 173-174; Page 6 IHC ADCY9 antibodies (1:1000, Abcam, ab191423, UK Line 177 Page 6 IHC rabbit secondary antibody (1:1000, SA00004-2, Proteintech, China)	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
<b>Cell lines:</b> Provide species information, strain.	Line 130; Page 5	
Provide accession number in repository <b>OR</b>	A549(SCSP-503) HCC82(TCHu153) H23(SCSP-581)	
supplier name, catalog number, clone number,	Line 133-134 Page 5	
OR RRID	BEAS-2B(CRL-9609) SPCA1(KG092)	
Primary cultures: Provide species, strain, sex of	n/a	n/a
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
<b>Laboratory animals:</b> Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID	n/a	n/a
Animal observed in or captured from the field: Provide species, sex and age where possible	n/a	n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID	n/a	n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession	n/a	n/a
number if available, and source (including location for collected wild specimens)		
Microbes: provide species and strain, unique accession number if available, and source	n/a	n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Line 404-407; Page 14	
equivalent committee(s), provide reference number	Approved by the Ethics Committee of the Affiliated	
for approval.	Hospital of Nantong University (No. S20200314-012).	
Provide statement confirming informed consent	n/a	n/a
obtained from study participants.		
Report on age and sex for all study participants.	n/a	n/a

# Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration	n/a	
number <b>OR</b> cite DOI in manuscript.		

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	Line 196; Page 7	
by-step protocols are available.	DNA Content Quantitation Assay (Cell Cycle, CA1510,	
	Solarbio, China)	
	Line 210; Page 7	
	Cell Apoptosis, CA1020-50T, Solarbio, Germany	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been	n/a	n/
done, or if they were not carried out.		а
Sample size determination	n/a	n/a
Randomisation	n/a	n/a
Blinding	n/a	n/a
Inclusion/exclusion criteria	n/a	n/

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	Line 163; Page 6	
replicated in laboratory	Three times	
	Line 182; Page 6	
	Three times	
	Line 206; Page 7	
	Three times	
	Line 221; Page 8	
	Three times	
	Line 230; Page 8	
	Three times	
	Line 251; Page 9	
	Three times	
Define whether data describe technical or biological	n/a	n,
replicates		а

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Line 404-407; Page 14	
authority granting ethics approval (IRB or equivalent	Approved by the Ethics Committee of the Affiliated	
committee(s), provide reference number for approval.	Hospital of Nantong University (No. S20200314-012).	
Studies involving experimental animals: State details	n/a	n/
of authority granting ethics approval (IRB or		а
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if	n/a	n/
relevant permits obtained, provide details of		а
authority approving study; if none were required,		
explain why.		

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,	n/a	n/
state the authority granting approval and reference		а
number for the regulatory approval		

# **Analysis**

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is	n/a	n/
excluded, and whether the criteria for exclusion were		а
determined and specified in advance.		

Yes (indicate where provided: section/paragraph)	n/a
Line 253-260; Page 9	
Welch's t test; Pearson's correlation; Student's t test	
Wilcox test	
	Line 253-260; Page 9 Welch's t test; Pearson's correlation; Student's t test

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	n/a	
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	Line 107; Page 4	
number in repository or DOI or URL.	Gene Expression Omnibus (GEO):	
	https://www.ncbi.nlm.nih.gov/geo/	
	database GSE42127	
	Line 109; Page 4	
	TCGA: https://portal.gdc.cancer.gov/	
	TCGA gdc_download_20210627—012856.195018	
If publicly available data are reused, provide	Line 107; Page 4	
accession number in repository or DOI or URL, where	Gene Expression Omnibus (GEO):	
possible.	https://www.ncbi.nlm.nih.gov/geo/	
	Line 109; Page 4	
	TCGA: https://portal.gdc.cancer.gov/	
	Line 121; Page 4	
	TIMER database: <a href="http://timer.comp-genomics.org/">http://timer.comp-genomics.org/</a>	
	Line 121; Page 4	
	CPTAC : https://proteomics.cancer.gov/programs/cptac	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	Line 112-125; Page 4 R software ROC package; cluster Profiler package; ggplot package; limma package; ggpubr package; ggextra package; reshaped package	
State whether the code or software is available.	n/a	n/a
If code is publicly available, provide accession number in repository, or DOI or URL.	n/a	n/ a

### Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with	(Please do not delete this sentence)	
the manuscript.		

Auticle information, https://dx.doi.org/10.21027/it4.22.1027
Article information: https://dx.doi.org/10.21037/jtd-22-1027